당뇨병콩팥병 진료지침 소개

키워드

참고문헌 (45)

1. GBD Chronic Kidney Disease Collaboration, "Global, regional, and national burden of chronic kidney disease, 1990-2017 : a systematic analysis for the Global Burden of Disease Study 2017", Lancet, 395, pp.709~733 (2020)
2. Jager KJ, "A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases", Nephrol Dial Transplant, 34, pp.1803~1805 (2019)
3. Kovesdy CP, "Epidemiology of chronic kidney disease : an update 2022", Kidney Int Suppl(2011), 12, pp.7~11 (2022)
4. Carney EF, "The impact of chronic kidney disease on global health", Nat Rev Nephrol, 16, pp.251~ (2020)
5. Sarnak MJ, "Kidney disease as a risk factor for development of cardiovascular disease : a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention", Circulation, 108, pp.2154~2169 (2003)
6. "2021 National Health Insurance Statistical Yearbook" (2022)[URL]
7. Aitken GR, "Change in prevalence of chronic kidney disease in England over time : comparison of nationally representative cross-sectional surveys from 2003 to 2010", BMJ Open, 4, pp.e005480~ (2014)
8. 안재희, "Prevalence and Determinants of Diabetic Nephropathy in Korea: Korea National Health and Nutrition Examination Survey", Diabetes and Metabolism Journal, 38(2), pp.109~119 (2014), 대한당뇨병학회[DOI]
9. "Trends in epidemiologic characteristics of end-stage renal disease from 2022 KORDS" (2023)[URL]
10. "2022 annual data report: epidemiology of kidney disease in the United States" (2022)[URL]
11. "Korean Society of Nephrology 2023practical recommendations for the management of diabetic kidney disease"[URL]
12. Kidney Disease: Improving Global Outcomes (KDIGO)Diabetes Work Group, "KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease", Kidney Int, 98, pp.S1~S115 (2020)
13. Kidney Disease : Improving Global Outcomes(KDIGO)Diabetes Work Group, "KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease", Kidney Int, 102, pp.S1~S127 (2022)
14. Navaneethan SD, "Diabetes management in chronic kidney disease : synopsis of the KDIGO 2022 clinical practice guideline update", Ann Intern Med, 176, pp.381~387 (2023)
15. Kidney Disease : Improving Global Outcomes(KDIGO)CKD Work Group, "KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease", Kidney Int Suppl, 3, pp.1~150 (2013)
16. Kidney Disease : Improving Global Outcomes(KDIGO)Lipid Work Group, "KDIGO clinical practice guideline for lipid management in chronic kidney disease", Kidney Int Suppl, 3, pp.259~305 (2013)
17. Kidney Disease : Improving Global Outcomes(KDIGO)Blood Pressure Work Group, "KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease", Kidney Int, 99, pp.S1~S87 (2021)
18. Ruospo M, "Glucose targets for preventing diabetic kidney disease and its progression", Cochrane Database Syst Rev, 6, pp.CD010137~ (2017)
19. Duckworth W, "Glucose control and vascular complications in veterans with type 2 diabetes", N Engl J Med, 360, pp.129~139 (2009)
20. Action to Control Cardiovascular Risk in Diabetes Study Group, "Effects of intensive glucose lowering in type 2 diabetes", N Engl J Med, 358, pp.2545~2559 (2008)
21. Shurraw S, "Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease : a population-based cohort study", Arch Intern Med, 171, pp.1920~1927 (2011)
22. Low S, "Impact of haemoglobin A1c trajectories on chronic kidney disease progression in type 2diabetes", Nephrology(Carlton), 24, pp.1026~1032 (2019)
23. Heerspink HJL, "Dapagliflozin in patients with chronic kidney disease", N Engl J Med, 383, pp.1436~1446 (2020)
24. Bhatt DL, "Sotagliflozin in patients with diabetes and chronic kidney disease", N Engl J Med, 384, pp.129~139 (2021)
25. The EMPA-KIDNEY Collaborative Group, "Empagliflozin in patients with chronic kidney disease", N Engl J Med, 388, pp.117~127 (2023)
26. Nuffield Department of Population Health Renal Studies Group, "Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes : collaborative meta-analysis of large placebo-controlled trials", Lancet, 400, pp.1788~1801 (2022)
27. Mosenzon O, "Dapagliflozin and prevention of kidney disease among patients with type 2diabetes : post hoc analyses from the DECLARE-TIMI 58trial", Diabetes Care, 45, pp.2350~2359 (2022)
28. Kraus BJ, "Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial", Kidney Int, 99, pp.750~762 (2021)
29. Oshima M, "Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice", Kidney Int, 99, pp.999~1009 (2021)
30. 고은실, "Intrarenal Mechanisms of Sodium-Glucose Cotransporter-2 Inhibitors on Tubuloglomerular Feedback and Natriuresis", Endocrinology and Metabolism, 38(4), pp.359~372 (2023), 대한내분비학회[DOI]
31. Tomson CRV, "Management of blood pressure in patients with chronic kidney disease not receiving dialysis : synopsis of the 2021 KDIGO clinical practice guideline", Ann Intern Med, 174, pp.1270~1281 (2021)
32. SPRINT Research Group, "A randomized trial of intensive versus standard bloodpressure control", N Engl J Med, 373, pp.2103~2116 (2015)
33. Bress AP, "Effect of intensive versus standard blood pressure treatment according to baseline prediabetes status : a post hoc analysis of a randomized trial", Diabetes Care, 40, pp.1401~1408 (2017)
34. Nazarzadeh M, "Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes : an individual participant-level data meta-analysis", Lancet Diabetes Endocrinol, 10, pp.645~654 (2022)
35. Keane WF, "The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy : the RENAAL study", Kidney Int, 63, pp.1499~1507 (2003)
36. Makino H, "Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes", Diabetes Care, 30, pp.1577~1578 (2007)
37. Bakris GL, "Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes", N Engl J Med, 383, pp.2219~2229 (2020)
38. Pitt B, "Cardiovascular events with finerenone in kidney disease and type 2 diabetes", N Engl J Med, 385, pp.2252~2263 (2021)
39. Agarwal R, "Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease : the FIDELITY pooled analysis", Eur Heart J, 43, pp.474~484 (2022)
40. Lv R, "Cardiovascularrenal protective effect and molecular mechanism of finerenone in type 2 diabetic mellitus", Front Endocrinol(Lausanne), 14, pp.1125693~ (2023)
41. de Boer IH, "Diabetes management in chronic kidney disease : a consensus report by the American Diabetes Association(ADA)and Kidney Disease : Improving Global Outcomes(KDIGO)", Kidney Int, 102, pp.974~989 (2022)
42. Martínez-Castelao A, "Optimizing the timing of nephrology referral for patients with diabetic kidney disease", Clin Kidney J, 14, pp.5~8 (2020)
43. Wavamunno MD, "The need for early nephrology referral", Kidney Int Suppl, 67, pp.S128~ (2005)[DOI]
44. Pugliese G, "Diabetic kidney disease : new clinical and therapeutic issues. Joint position statement of the Italian Diabetes Society and the Italian Society of Nephrology on"The natural history of diabetic kidney disease and treatment of hyperglycemia in patients with type 2 diabetes and impaired renal function"", Nutr Metab Cardiovasc Dis, 29, pp.1127~1150 (2019)
45. Hingwala J, "Risk-based triage for nephrology referrals using the kidney failure risk equation", Can J Kidney Health Dis, 4, pp.2054358117722782~ (2017)

관련 논문AI추천